Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anavex Lf SC (NQ: AVXL )

8.610 -0.070 (-0.81%)
Streaming Delayed Price Updated: 2:23 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Anavex Lf SC

< Previous 1 2 3 4 5 Next >
Wall Street Thinks This Small-Cap Stock Can Quadruple in Value
The company generates no revenue, but it may be worth taking a chance on as it possesses lots of upside. 
Via The Motley Fool
Why Shares of Anavex Life Sciences Rose 12.4% in February
The company's first-quarter earnings report detailed positive news regarding its pipeline. 
Via The Motley Fool
Is Anavex Life Sciences Stock a Buy Now?
A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business. 
Via The Motley Fool
This Short-Squeeze Candidate Could Actually Pan Out in the Long Run
Short-sellers have piled into this clinical-stage biopharma stock. 
Via The Motley Fool
Why Anavex Life Sciences Stock Bolted Higher in January
The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results. 
Via The Motley Fool
Anavex Life Sciences Stock Shows Improved Price Strength Rating
Anavex Life Sciences stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 75. 
Via Investor's Business Daily
Earnings Preview: Anavex Life Sciences
 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today
 
Via Benzinga
Here's How Much $100 Invested In Anavex Life Sciences 5 Years Ago Would Be Worth Today
 
Via Benzinga
Here's How Much You Would Have Made Owning Anavex Life Sciences Stock In The Last 5 Years
 
Via Benzinga
3 Biotech Stocks Under $15 Worth a Second Look in 2023
All three stocks have promising therapies that could drive revenue in the coming years. 
Via The Motley Fool
Top Picks For 2023: Anavex Life Sciences
Anavex is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases, with encouraging results in Alzheimer’s, Parkinson’s, and Rett... 
Via Talk Markets
Tesla To $205? Here Are 10 Other Price Target Changes For Tuesday
Goldman Sachs cut Tesla, Inc. (NASDAQ: TSLA) price target from $235 to $205. Goldman Sachs analyst Mark Delaney maintained a Buy rating on the stock. Tesla shares fell 2.6% to $119.93 in pre-market... 
Via Benzinga
Analyzing Anavex Life Sciences's Short Interest
Anavex Life Sciences's (NASDAQ:AVXL) short percent of float has risen 17.06% since its last report. The company recently reported that it has 11.91 million shares sold short, which is 15.71% of all... 
Via Benzinga
Anavex Life Sciences Stock Could 5x Before 2025 -- Here's Why
The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data. 
Via The Motley Fool
Anavex Catapults On Alzheimer's Results — But Math Question Clouds The Data
A math error could have clouded the drug's actual benefits. 
Via Investor's Business Daily
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,500 Today
 
Via Benzinga
Is Anavex Life Sciences a Buy?
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
 
Via Benzinga
Is Anavex Life Sciences a Smart Stock to Buy Now?
The company's Alzheimer's disease drug just succeeded in a clinical trial. Or did it? 
Via The Motley Fool
Dow Drops 100 Points; Asana Shares Plummet
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 100 points on Friday. 
Via Benzinga
Why Cracker Barrel Shares Are Trading Lower By Around 13%? Here Are 42 Stocks Moving In Friday's Mid-Day Session
Gainers Yunhong CTI Ltd. (NASDAQ: CTIB) rose 42% to $0.54 after dipping 56% on Thursday. 
Via Benzinga
Anavex Life Sciences (NASDAQ: AVXL) Says Phase 2b/3 for ANAVEX2-73 Met Primary and Secondary Endpoints Reducing Cognative Decline in Patients with Early Alzheimer’s
Anavex Life Sciences Corp. (NASDAQ: AVXL) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and 
Via Spotlight Growth
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Gold Down 1%; Samsara Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones falling around 75 points on Friday. 
Via Benzinga
Why Anavex Life Sciences Stock Is Surging Today
The biotech reported positive results from a phase 2b/3 study of its lead Alzheimer's disease candidate. 
Via The Motley Fool
Rigel Pharmaceuticals (RIGL) Stock Soars on FDA Approval News
Rigel Pharmaceuticals (RIGL) stock is heading higher on Friday after getting approval from the FDA for its leukemia treatment. 
Via InvestorPlace
Why Is Anavex Life Sciences (AVXL) Stock Up 30% Today?
Anavex Life Sciences (AVXL) stock is rocketing higher on Friday following positive results from an Alzheimer’s clinical trial. 
Via InvestorPlace
Smartsheet, Samsara, Anavex Life Sciences And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly lower, with the Dow Jones dropping over 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Dow Tumbles 300 Points After US Economy Adds 263,000 Jobs
U.S. stocks traded lower this morning, with the Dow Jones falling more than 300 points on Friday following the release of jobs data for November. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.